As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean.
WSJ.com: Heard on the Street, Wall Street Journal: Markets: Heard on the Street
Mon, 02/19/2018 - 8:18am
As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean.